Human population-based identification of CD4+ T-cell peptide epitope determinants

被引:13
作者
Stickler, M
Chin, R
Faravashi, N
Gebel, W
Razo, OJ
Rochanayon, N
Power, S
Valdes, AM
Holmes, S
Harding, FA
机构
[1] Genecor Int, Palo Alto, CA 94304 USA
[2] Dept Med & Endocrinol, Rome, Italy
[3] Stanford Univ, Dept Stat, Stanford, CA 94305 USA
关键词
antigens/peptides/epitopes; human; CD4(+) T cells;
D O I
10.1016/S0022-1759(03)00279-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A human cell-based method to identify functional CD4(+) T-cell epitopes in any protein has been developed. Proteins are tested as synthetic 15-mer peptides offset by three amino acids. Percent responses within a large donor population are tabulated for each peptide in the set. Peptide epitope regions are designated by difference in response frequency from the overall background response rate for the compiled dataset. Epitope peptide responses are reproducible, with a median coefficient of variance of 21% when tested on multiple random-donor sets. The overall average response rate within the dataset increases with increasing putative human population antigenic exposure to a given protein. The background rate was high for HPV16 E6, and was low for human-derived cytokine proteins. The assay identified recall epitope regions within the donor population for the protein staphylokinase. For an industrial protease with minimal presumed population exposure, immunodominant epitope peptides were identified that were found to bind promiscuously to many HLA class II molecules in vitro. The peptide epitope regions identified in presumably unexposed donors represent a subset of the total recall epitopes. Finally, as a negative control, the assay found no peptide epitope regions in human beta2-microglobulin. This method identifies functional CD4+ T-cell epitopes in any protein without pre-selection for HLA class II, suggests whether a donor population is pre-exposed to a protein of interest, and does not require sensitized donors for in vitro testing. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:95 / 108
页数:14
相关论文
共 47 条
[1]   The optimization of helper T lymphocyte (HTL) function in vaccine development [J].
Alexander, J ;
Fikes, J ;
Hoffman, S ;
Franke, E ;
Sacci, J ;
Appella, E ;
Chisari, FV ;
Guidotti, LG ;
Chesnut, RW ;
Livingston, B ;
Sette, A .
IMMUNOLOGIC RESEARCH, 1998, 18 (02) :79-92
[2]   RANKING POTENTIAL BINDING PEPTIDES TO MHC MOLECULES BY A COMPUTATIONAL THREADING APPROACH [J].
ALTUVIA, Y ;
SCHUELER, O ;
MARGALIT, H .
JOURNAL OF MOLECULAR BIOLOGY, 1995, 249 (02) :244-250
[3]   Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines [J].
Asai, T ;
Storkus, WJ ;
Whiteside, TL .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2000, 7 (02) :145-154
[4]   Lymphocyte kinetics: the interpretation of labelling data [J].
Asquith, B ;
Debacq, C ;
Macallan, DC ;
Willems, L ;
Bangham, CRM .
TRENDS IN IMMUNOLOGY, 2002, 23 (12) :596-601
[5]  
BERZOFSKY JA, 1993, ANN NY ACAD SCI, V690, P256
[6]   Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].
Casadevall, N ;
Nataf, J ;
Viron, B ;
Kolta, A ;
Kiladjian, J ;
Martin-Dupont, P ;
Michaud, P ;
Papo, T ;
Ugo, V ;
Teyssandier, I ;
Varet, B ;
Mayeux, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475
[7]   HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles [J].
Doolan, DL ;
Southwood, S ;
Chesnut, R ;
Appella, E ;
Gomez, E ;
Richards, A ;
Higashimoto, YI ;
Maewal, A ;
Sidney, J ;
Gramzinski, RA ;
Mason, C ;
Koech, D ;
Hoffman, SL ;
Sette, A .
JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :1123-1137
[8]   Human CD4(+) T-cell recognition of influenza A virus hemagglutinin after subunit vaccination [J].
Gelder, CM ;
Lamb, JR ;
Askonas, BA .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4787-4790
[9]   A COMPARISON STUDY OF HUMAN PAPILLOMAVIRUS PREVALENCE BY THE POLYMERASE CHAIN-REACTION IN LOW-RISK WOMEN AND IN A GYNECOLOGY REFERRAL GROUP AT ELEVATED RISK FOR CERVICAL-CANCER [J].
GOLDSBOROUGH, MD ;
MCALLISTER, P ;
REID, R ;
TEMPLE, G ;
LORINCZ, AT .
MOLECULAR AND CELLULAR PROBES, 1992, 6 (06) :451-457
[10]  
GUERY JC, 1995, J IMMUNOL, V154, P545